Literature DB >> 21911310

Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.

Young-Ah Cho1, Hye-Jung Yoon, Jae-Il Lee, Sam-Pyo Hong, Seong-Doo Hong.   

Abstract

Tumor-infiltrating lymphocytes (TILs) are considered to represent immune reactions of the host to a malignant tumor. Programmed death receptor ligand-1 (PD-L1) is a surface protein that blocks the function of T lymphocytes and is expressed on cancer cells. Tumor-associated fibroblasts (TAFs), which influence tumor growth have also been reported to express PD-L1 and thus inhibit TILs. In the present study, we investigated the densities of CD4(+)/CD8(+) TILs, PD-L1 expression of tumor cells and TAFs in oral squamous cell carcinoma (OSCC). Forty-five cases of OSCC were selected. We evaluated PD-L1 expression and the infiltration degree of each lymphocyte by immunohistochemical examination. These data were analyzed in connection with clinicopathological factors. Peritumoral CD8(+) TILs were observed in every patient with OSCC, and their densities were correlated with lymph node metastasis (P<0.001), tumor size (P=0.003), and clinical stage (P<0.001). PD-L1 expression on OSCC cells was observed in 39 cases and was associated with the lower density of intratumoral CD8(+) TILs (P=0.047). PD-L1 expression of tumors <4cm in size was correlated with the histological grade of the tumor (P=0.022). TAFs were positive for PD-L1 in 18 cases. Peritumoral TILs were significantly associated with tumor size, lymph node metastasis and clinical stage. Though PD-L1 expressed by OSCC cells did not affect patients' survival, its correlation with decreased number of intratumoral TILs suggests that the development of a strategy to block the interactions of PD-L1 with TIL would be a useful tool for inhibiting tumor growth.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21911310     DOI: 10.1016/j.oraloncology.2011.08.007

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  90 in total

1.  Immunotherapy for Head and Neck Squamous Cell Carcinoma.

Authors:  Rebecca C Hoesli; Jeffrey S Moyer
Journal:  Curr Oral Health Rep       Date:  2016-03-12

2.  Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma.

Authors:  Douglas J Hartman; Fahad Ahmad; Robert L Ferris; David L Rimm; Liron Pantanowitz
Journal:  Oral Oncol       Date:  2018-10-11       Impact factor: 5.337

Review 3.  Promising systemic immunotherapies in head and neck squamous cell carcinoma.

Authors:  Neil Gildener-Leapman; Robert L Ferris; Julie E Bauman
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

Review 4.  The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Authors:  Panagiota Economopoulou; Christos Perisanidis; Evaggelos I Giotakis; Amanda Psyrri
Journal:  Ann Transl Med       Date:  2016-05

Review 5.  AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma.

Authors:  Cory D Fulcher; Missak Haigentz; Thomas J Ow
Journal:  Head Neck       Date:  2017-11-24       Impact factor: 3.147

6.  PD-L1 expression in triple-negative breast cancer.

Authors:  Elizabeth A Mittendorf; Anne V Philips; Funda Meric-Bernstam; Na Qiao; Yun Wu; Susan Harrington; Xiaoping Su; Ying Wang; Ana M Gonzalez-Angulo; Argun Akcakanat; Akhil Chawla; Michael Curran; Patrick Hwu; Padmanee Sharma; Jennifer K Litton; Jeffrey J Molldrem; Gheath Alatrash
Journal:  Cancer Immunol Res       Date:  2014-01-10       Impact factor: 11.151

Review 7.  Emerging drugs for head and neck cancer.

Authors:  Yihui Wen; Jennifer R Grandis
Journal:  Expert Opin Emerg Drugs       Date:  2015-03-31       Impact factor: 4.191

8.  Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal.

Authors:  Van K Morris; Asif Rashid; Miguel Rodriguez-Bigas; Prajnan Das; George Chang; Aki Ohinata; Jane Rogers; Christopher Crane; Robert A Wolff; Cathy Eng
Journal:  Oncologist       Date:  2015-09-17

Review 9.  Metastatic disease in head & neck oncology.

Authors:  Paolo Pisani; Mario Airoldi; Anastasia Allais; Paolo Aluffi Valletti; Mariapina Battista; Marco Benazzo; Roberto Briatore; Salvatore Cacciola; Salvatore Cocuzza; Andrea Colombo; Bice Conti; Alberto Costanzo; Laura Della Vecchia; Nerina Denaro; Cesare Fantozzi; Danilo Galizia; Massimiliano Garzaro; Ida Genta; Gabriela Alejandra Iasi; Marco Krengli; Vincenzo Landolfo; Giovanni Vittorio Lanza; Mauro Magnano; Maurizio Mancuso; Roberto Maroldi; Laura Masini; Marco Carlo Merlano; Marco Piemonte; Silvia Pisani; Adriele Prina-Mello; Luca Prioglio; Maria Gabriella Rugiu; Felice Scasso; Agostino Serra; Guido Valente; Micol Zannetti; Angelo Zigliani
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-04       Impact factor: 2.124

Review 10.  The Microenvironment of Tongue Cancer.

Authors:  Want Tao; Zeng Li-Juan; Li Kan; Li Jing-Yuan; Liu Xiang-Qi; Liang Yu-Jie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.